Edition:
United Kingdom

Exelixis Inc (EXEL.OQ)

EXEL.OQ on NASDAQ Stock Exchange Global Select Market

28.99USD
21 Feb 2018
Change (% chg)

-- (--)
Prev Close
$28.99
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
879,358
52-wk High
$32.49
52-wk Low
$18.04

Chart for

About

Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's... (more)

Overall

Beta: 1.90
Market Cap(Mil.): $7,556.29
Shares Outstanding(Mil.): 293.90
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Exelixis Announces Results From A Phase 2 Trial Of Cabozantinib In The First-Line Treatment Of Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma

* EXELIXIS ANNOUNCES RESULTS FROM A PHASE 2 INVESTIGATOR-SPONSORED TRIAL OF CABOZANTINIB IN THE FIRST-LINE TREATMENT OF METASTATIC RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CARCINOMA

13 Feb 2018

BRIEF-Exelixis Announces Updated Phase 1 Trial Results For Cabozantinib

* EXELIXIS ANNOUNCES UPDATED PHASE 1 TRIAL RESULTS FOR CABOZANTINIB IN COMBINATION WITH NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN REFRACTORY GENITOURINARY (GU) TUMORS Source text for Eikon: Further company coverage:

07 Feb 2018

BRIEF-Ipsen And Exelixis Announce Phase 3 Trial Results Of Cabozantinib Showing Benefit In Hepatocellular Carcinoma Patients

* EXELIXIS AND IPSEN ANNOUNCE PHASE 3 TRIAL RESULTS OF CABOZANTINIB DEMONSTRATING SIGNIFICANT OVERALL SURVIVAL BENEFIT IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA

16 Jan 2018

BRIEF-Exelixis Enters Into Exclusive Collaboration And License Agreement With Stemsynergy Therapeutics

* EXELIXIS - ENTERED INTO EXCLUSIVE COLLABORATION AND LICENSE AGREEMENT WITH STEMSYNERGY THERAPEUTICS

08 Jan 2018

BRIEF-Exelixis Announces Amendment To Protocol For Phase 1B Trial Of Cabozantinib In Combination With Atezolizumab

* EXELIXIS INC - AMENDMENT TO PROTOCOL FOR PHASE 1B TRIAL OF CABOZANTINIB IN COMBINATION WITH ATEZOLIZUMAB

04 Jan 2018

Pfizer, Exelixis cancer drugs get FDA approval for wider use

Cancer treatments from Pfizer Inc and Exelixis Inc on Tuesday won approval from the U.S. Food and Drug Administration for expanded use in previously untreated patients.

19 Dec 2017

Pfizer, Exelixis cancer drugs get FDA approval for wider use

Dec 19 Cancer treatments from Pfizer Inc and Exelixis Inc on Tuesday won approval from the U.S. Food and Drug Administration for expanded use in previously untreated patients.

19 Dec 2017

BRIEF-Exelixis Announces FDA Approval Of Cabometyx Tablets For Previously Untreated Advanced Renal Cell Carcinoma

* EXELIXIS ANNOUNCES U.S. FDA APPROVAL OF CABOMETYX® (CABOZANTINIB) TABLETS FOR PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA

19 Dec 2017

BRIEF-FDA Says Approved Exelixis' sNDA For Patients With Previously Untreated Advanced RCC

* FDA SAYS APPROVED EXELIXIS' SNDA FOR PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED RCC

19 Dec 2017

BRIEF-Exelixis reports Q3 earnings per share $0.26

* Exelixis announces third quarter 2017 financial results and provides corporate update

01 Nov 2017

Competitors

Earnings vs. Estimates